AI-Based Personalized Exercise Prescription Through Mobile Health on Physical Activity and Health Outcomes in Older Adults: A Feasibility Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorThe University of Tennessee, Knoxville

About this trial

The purpose of this research is to investigate the feasibility, acceptability, appropriateness, and preliminary efficacy of a wearable and artificial intelligence-driven mobile application-based exercise prescription grounded in self-determination theory (SDT) and behavioral change techniques (BCTs) among older adults. As no data exists on the feasibility of AI-driven exercise programs grounded in SDT and multiple BCTs specifically for older adults, this will be a pioneering study to explore the feasibility of wearable and AI-driven exercise program protocols and the rates of acceptance and appropriateness of the exercise prescription intervention among older adults. In addition, this study will test the preliminary efficacy of the intervention on physical activity (PA), mental health, and quality of life. This study follows the National Institute of Health (NIH) stage model, and it represents stage 1b of the NIH stage model, which emphasizes the feasibility and actionable processes for delivering a new health intervention. Specifically, this study will: 1.Evaluate the research protocol feasibility of a wearable and AI-driven mobile application-based exercise prescription grounded in SDT and BCTs (of goal setting, self-monitoring, graded task, and demonstration) on older adults over 8 weeks 2. Evaluate the acceptability and appropriateness of a wearable, AI-driven, mobile application-based exercise prescription grounded in SDT and BCTs among older adults over 8 weeks. 3. Evaluate the preliminary impact of a wearable and AI-driven mobile application-based exercise prescription grounded in SDT and BCTs on older adult PA (steps per day and daily duration of light PA and Moderate-vigorous PA), sedentary time, sleep, mental health (depression and anxiety), and quality of life.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Be aged 65 years or older.

Own a smartphone (Android or iOS) compatible with study applications.

Have reliable access to the internet or Wi-Fi.

Demonstrate basic digital literacy sufficient to operate a smartphone (e.g., ability to open applications, navigate simple interfaces, and follow on-screen instructions), with or without initial guidance from the research staff.

Disqualifiers

Are younger than 65 years of age.

Do not own a compatible smartphone (Android or iOS) or do not have reliable internet/Wi-Fi access.

Are deemed unable to safely participate in physical activity based on the screening process (including PAR-Q+, STEADI, and research staff assessment), or do not obtain required physician clearance when indicated.

Currently meet or exceed 150 minutes of moderate-to-vigorous physical activity (MVPA) per week.

Trial design

Design model

Single group

Treatments tested in this trial

  • Fitness app powered by AI and wearable device

    Other intervention

    All participants will be provided the researcher-developed sFitRx mHealth application. sFitRx will provide participants with an established daily and weekly exercise prescription program based on each participant's: (1) daily step goals, (2) previous week's PA, as collected by the Fitbit Flex 2; and (3) current physical conditioning and well-being, as collected by sFitRx. The sFitRx will provide participants with a video demonstration of warm up exercise and all prescribed exercise types, including aerobics, resistance, balance, and flexibility exercises. These exercises follow a graded task BCT. The exercise program delivered by the sFitRx app is grounded in self-determination theory, most especially in satisfying the basic psychological needs that drive intrinsic motivation.

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Single-armExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Recruitment

Number screened/month per recruitment method

Time frame
Pre-intervention
2

Enrollment

Number excluded by criterion; Number that decline participation; Reason for declining participation (open-ended); Average time from screening to enrollment (minutes/hours/days/month).

Time frame
Pre-intervention
3

Participant Dropout Rate

Number dropouts from AI-based exercise intervention; Reason for dropout (open-ended).

Time frame
Baseline (week 1) - Follow up (Week 10)
4

Retention

Number that completed the intervention program

Time frame
Baseline (week 1) - Follow up (Week 10)

Secondary outcomes

1

Fitbit Daily Step

Fitbit Flex 2 will be used to assess participants' daily steps

Time frame
Baseline (week 0) and Follow up (week 10)
2

Physical Activity

We will use the Physical Activity Scale for the Elderly to assess PA across leisure (6-item question), household (3-item question), and occupational domains (1-item question) over the past 7 days. Higher scores means more physical activity. (Low activity: \<100; Moderate: 100-250; High: \>250)

Time frame
Baseline (week 1) and Follow up (Week 10)
3

Depression

Depression will be measured using Patient Health Questionnaire (PHQ-8), a 8-item symptom severity rating scale for depression (Kroenke et al., 2009). PHQ-8 is a validated diagnostic and severity measure of symptoms of depressive disorders. Adults with scores of 0-4 are considered to have no or minimal symptoms of depression. Score 5-9 are considered mild symptom Score 10-14 are considered moderate symptom Score 15-24 are considered severe symptom

Time frame
Baseline (week 0) and Follow up (week 10)
4

Anxiety

Anxiety will be assessed using the Geriatric Anxiety Scale (GAS). GAS is a 10-item rating scale on a 4-Likert Scale (Not at all \[0\] to All of the time \[3\]). Item 1 through 10 are summed to provide a total score. The higher the score, the worse the anxiety outcome. Score 1-6 are considered minimal symptom Score 7-9 are considered mild symptom Score 10 is considered moderate Score 12-30 are considered severe symptom

Time frame
Baseline (week 0) and Follow up (week 10)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.